Vanderbilt University

Vanderbilt University, founded in 1873, is a prominent private research institution located in the United States, serving approximately 6,500 undergraduates and 5,300 graduate and professional students. The university comprises ten schools, including the highly regarded Peabody College, which is ranked as the top Graduate School of Education by U.S. News and World Report. Vanderbilt offers a diverse array of undergraduate and graduate programs across various disciplines, including the liberal arts, sciences, engineering, music, education, and human development. With a distinguished medical center and a public policy center, Vanderbilt is recognized as one of the nation's top 20 universities, with numerous programs consistently placed in the top 10 across multiple fields. As a non-profit organization, Vanderbilt is dedicated to advancing education and research while fostering a vibrant academic community.

Anders Hall

Vice Chancellor for Investments and Chief Investment Officer

Hunter McCrossin

Managing Director for Private Investments

Priti Mody

Investment Manager of Private Equity and Venture Capital

Roy Yum

Investment Manager of Private Investments

6 past transactions

Aumni

Series B in 2021
Aumni is a data-driven investment management platform based in the United States that serves the venture capital industry. It offers a portfolio intelligence solution that helps venture capital firms enhance their operational efficiency and gain a competitive edge. Aumni's platform audits, analyzes, and visualizes key data from venture capital deal documents, extracting hundreds of data points to track critical insights, including investment rights, portfolio performance, and emerging investment trends. By converting complex deal data into a clear and error-free dataset, Aumni enables investors and venture firms to make informed strategic decisions and streamline their daily operations. The platform is designed for forward-thinking investment teams aiming to unlock and structure the vast amounts of untapped data within their portfolios.

Monzo

Series G in 2020
Monzo Bank Limited is a digital-only bank based in London, United Kingdom, offering a range of financial services including current accounts, savings accounts, overdrafts, and loans for both individuals and businesses. Established in 2015 and rebranded from FOCUS FS LIMITED in 2016, Monzo focuses on providing an efficient online banking experience through its mobile application, catering to tech-savvy customers who prefer managing their finances without traditional bank branches. The platform allows users to spend, save, and manage their money seamlessly, with real-time balance updates, intelligent notifications, and comprehensive tracking of transactions. Monzo aims to serve as a central hub for users' financial activities, enhancing their overall banking experience.
The University of Texas’s Medical Branch in Galveston, Texas, strives to enable students to become leading practitioners, teachers, and investigators in the healthcare field. Academics at the UT Medical Branch are available through four different schools, each with its own specialization: * School of Medicine * School of Nursing * School of Health Professions * Graduate School of Biomedical Sciences In addition to programs in these schools, the Medical Branch also offers three combined MD-PhD degrees: Biomedical Sciences, Medical Humanities, and Biomedical Engineering. Graduate students may enroll in their choice of more than 25 residencies and 35 subspecialty fellowship programs, gaining real world experience for their future career in professional environments. Some of these programs are: * Aerospace Medicine * Anesthesiology * Dermatology * Internal Medicine * Obstetrics and Gynecology * Ophthalmology * Radiation Oncology * And many more On-campus housing is not offered, but the school provides information of nearby housing options. Financial aid is available to eligible students through federal work study, scholarships, and student loans.

Pathfinder Therapeutics

Series A in 2008
Pathfinder Therapeutics

ActivBiotics

Series A in 2002
ActivBiotics develops and sells antibiotics and combination therapies for the treatment of acute and chronic infections. The company’s lead product candidate, Rifalazil, is a proprietary, orally administered antibacterial agent which is in a Phase III clinical trial for the treatment of intermittent claudication associated with peripheral arterial disease. The company’s other product candidate, M40403, is a proprietary small molecule to mimic the function of a naturally occurring enzyme, which plays a role in various inflammatory disease states. It also develops ABI-0043 as a proprietary antibacterial agent for the treatment of complicated skin and skin structure infections caused by Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus. In addition, the company identifies product candidates from its proprietary compound libraries for the treatment of inflammatory diseases and bacterial infections. The company’s superoxide dismutases (SOD) mimetic library consists of approximately 250 small molecules that mimic naturally occurring SOD enzymes.